Zanidatamab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HER2 |
| Clinical data | |
| Trade names | Ziihera |
| Other names | ZW25, zanidatamab-hrii |
| License data |
|
| Routes of administration | Intravenous infusion |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C5553H8526N1482O1726S36 |
| Molar mass | 124818.10 g·mol−1 |
Zanidatamab, sold under the brand name Ziihera, is a humanized monoclonal antibody used for the treatment of HER2-positive biliary tract cancer. It is an IgG-like bispecific HER2-directed antibody directed against two non-overlapping domains of HER2. Zanidatamab is produced in Chinese hamster ovary cells.
The most common adverse reactions include diarrhea, infusion-related reaction, abdominal pain, and fatigue.
Zanidatamab was approved for medical use in the United States in November 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.